Trump may be mystery patient in odd case of 79yo getting experimental obesity drug

GoKawiil's interpretation of the reporting above, not reported fact.

This unusual case highlights the potential for high-profile individuals to access experimental treatments through regulatory pathways, raising questions about equity and transparency in drug access. It underscores the urgent need for broader availability of promising obesity therapies, which could significantly impact millions struggling with weight management and related health conditions.

• The case involves early access to Eli Lilly’s experimental obesity drug retatrutide via the FDA's compassionate use program.
• It raises concerns about fairness and transparency in granting access to cutting-edge treatments, especially for high-profile patients.
• The development of retatrutide could revolutionize obesity treatment, offering substantial weight loss comparable to bariatric surgery.